Leucovorin for young children with autism language difficulties
Part of Brain & nervous system, Mental health clinical trials.
This Phase 2 study tests whether leucovorin (a vitamin-related medicine) can improve social communication and language in young children with autism. It also looks at safety and whether the results hold while the child stays on their usual therapies and routines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has a confirmed autism diagnosis using standard autism testing (ADOS-2 or ADI-R).
- Your child is between 2 years 6 months and 5 years 2 months old.
- Blood test shows your child is positive for folate receptor alpha autoantibodies (FRAA).
- Your child has meaningful language difficulty and speaks English at home/school (English included in your child’s upbringing).
- Your child can participate in social tasks and tolerate brain-imaging/testing procedures.
- Your child must keep all current therapies/diets/behavior supports the same for the study period (and for 2 months before joining).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medication called TB006 for adults with autism. It aims to see if it can help reduce symptoms. Participants must be 18–35, have moderate-to-severe autism, and have a caregiver who can join them.
This study tests whether folinic acid (a B-vitamin supplement) can help improve autism symptoms in children ages 3–6. Folinic acid may support brain function, and researchers want to see if it works better than placebo (a dummy pill).
This study tests whether folinic acid (a type of B vitamin) can help improve symptoms of autism in children. Researchers want to see if this supplement, combined with your child's current treatments, might make a difference.
This study tests whether an antioxidant supplement (something that fights cell damage) can help children with autism. It lasts 3 months and requires that the child stays on their current treatments without changes.
This Phase 2 study tests CBDV, a form of cannabis-based medicine, compared with placebo (dummy medicine) in children with autism who have significant irritability and social challenges. It aims to see whether CBDV can improve behavior and overall symptom severity safely over the study period.
This Phase 2 study tests whether esomeprazole helps children with autism. It looks at children who are generally healthy, take stable medicines, and can reliably attend visits so their care team can track changes during the study.
Hear when a new Autism spectrum disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.